“Dar”-ing to target CD38 in T-ALL

Abstract

In this issue of Blood, Bride et al show that CD38 is expressed on pediatric T-cell acute lymphoblastic leukemia (T-ALL) at the time of diagnosis, after induction treatment, and at the time of relapse and that targeting CD38 with the monoclonal antibody daratumumab shows great efficacy in multiple patient-derived xenograft (PDX) models of T-ALL.